Specialty Pharmacy

Clonidine topical gel fails to achieve desired outcome in reducing pain from diabetic neuropathy.

Scientists have developed a new tool to test current strategies for finding mutant gene cancer drivers.

Regular use of over-the-counter, anti-inflammatory drugs associated with an increased risk of death in patients with cancer.

Administering immunotherapy near the tumor site prevents adverse events associated with the current administration method.

Undisclosed academic and financial conflicts of interest may influence analysis of clinical research.

Investigative drug may improve overall survival and reduce chemotherapy-induced heart damage in children with acute myelogenous leukemia.

Cisplatin used in combination with sodium thiosulfate significantly reduced the incidence of hearing loss in pediatric cancer patients.

Study finds link between aspirin and blood platelets in cancer cells.

Novel immunotherapy shows promise treating patients with leukemia at high-risk of relapse.

Studies find varying results in incidence of strokes from wet age-related macular degeneration treatment.

Ocrelizumab achieves primary endpoints treating primary progressive multiple sclerosis.

Specialty pharmacies have multiple decisions to make for clinical programs that accompany a contract with a manufacturer.

FDA extends biologics license application review for MS drug ocrelizumab (Ocrevus) to allow for more information on manufacturing process.

Niraparib is an investigational PARP inhibitor currently being evaluated for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers.

Metastasis affects as many as 5% of cancer patients around the world.

Top news of the day from across the health care landscape.

The FDA granted orphan drug designation to nintedanib, a triple angiokinase inhibitor, for the treatment of mesothelioma.

Syringe services programs seek to halt the spread of HIV among injection drug users.

After 2 years of exclusion, Harvoni has been added to the Express Scripts national formulary for the treatment of hepatitis C.

Cyclin-dependent kinase inhibitor reduces Ki67 expression and shows promise in breast cancer treatment.

HIV infection continues to rise in across European countries.

Top news of the day from across the health care landscape.

When treatment with DMARDs does not work, biologic agents are used to treat RA.

Lack of adherence to HIV medications can create resistance since the virus mutates quickly.

Risankizumab achieved higher rates of clinical response in patients with Crohn’s disease.

Pennsylvania health department recommends that patients be screened for HIV, and hepatitis B and C viruses.

FDA grants accelerated approval for rucaparib (Rubraca) to treat advanced ovarian cancer.

Pembrolizumab was associated with clinically meaningful improvements in quality of life over chemotherapy.